<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>)polymerase (PARP, EC 2.4.2.30), an abundant nuclear protein activated by DNA nicks, mediates cell <z:hpo ids='HP_0011420'>death</z:hpo> in vitro by <z:chebi fb="0" ids="13389">nicotinamide adenine dinucleotide</z:chebi> (<z:chebi fb="0" ids="13389">NAD</z:chebi>) <z:mpath ids='MPATH_63'>depletion</z:mpath> after exposure to nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The authors examined whether genetic deletion of PARP (PARP null mice) or its pharmacologic inhibition by 3-aminobenzamide (3-AB) attenuates tissue injury after transient <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-two hours after reperfusion following 2 hours of filamentous middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, ischemic injury was decreased in PARP-/- and PARP+/- mice compared with PARP+/+ litter mates, and also was attenuated in 129/SV <z:mp ids='MP_0002169'>wild-type</z:mp> mice after 3-AB treatment compared with controls </plain></SENT>
<SENT sid="3" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> sparing was accompanied by functional recovery in PARP-/- and 3-AB-treated mice </plain></SENT>
<SENT sid="4" pm="."><plain>Increased poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) immunostaining observed in ischemic cell nuclei 5 minutes after reperfusion was reduced by 3-AB treatment </plain></SENT>
<SENT sid="5" pm="."><plain>Levels of <z:chebi fb="0" ids="13389">NAD</z:chebi>--the substrate of PARP--were reduced 2 hours after reperfusion and were 35% of contralateral levels at 24 hours </plain></SENT>
<SENT sid="6" pm="."><plain>The decreases were attenuated in PARP-/- mice and in 3-AB-treated animals </plain></SENT>
<SENT sid="7" pm="."><plain>Poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>)polymerase cleavage by caspase-3 (CPP-32) has been proposed as an important step in apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Markers of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, such as oligonucleosomal DNA damage, total DNA fragmentation, and the density of terminal deoxynucleotidyl transferase <z:chebi fb="0" ids="17625">dUTP</z:chebi> nick-end-labelled (TUNEL +) cells, however, did not differ in ischemic brain tissue of PARP-/- mice or in 3-AB-treated animals versus controls, although there were differences in the number of TUNEL-stained cells reflecting the decrease in <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, ischemic brain injury activates PARP and contributes to cell <z:hpo ids='HP_0011420'>death</z:hpo> most likely by <z:chebi fb="0" ids="13389">NAD</z:chebi> <z:mpath ids='MPATH_63'>depletion</z:mpath> and energy failure, although the authors have not excluded a role for PARP in apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> at earlier or later stages in ischemic cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Inhibitors of PARP activation could provide a potential therapy in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>